Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents - Kubasch, Anne Sophie; Schulze, Freya; Giagounidis, Aristoteles; Götze, Katharina S.; Krönke, Jan; Sockel, Katja; Middeke, Jan Moritz; Chermat, Fatiha; Gloaguen, Silke; Puttrich, Martin; Weigt, Carmen; William, Doreen; et al. (Leukemia, 2020)
Published online: 3 December 2019